Scientists Still Shoot For the Moon With Patent-Free Covid Drug

An anonymous reader quotes a report from Bloomberg, written by Naomi Kresge: In the early days of the Covid-19 pandemic, hundreds of scientists from all over the world banded together in an open-source effort to develop an antiviral that would be available for all. They could never have anticipated the many roadblocks they would face along the way, including the Russian invasion of Ukraine, which made refugees out of a group of Kyiv chemists who were doing important work for the project. The group, which called itself Covid Moonshot, hasn't given up on its effort to introduce a more affordable, patent-free treatment for the virus. Their open-source Covid antiviral, now funded by Wellcome, is on track to be ready for human testing within the next year and a half, according to Annette von Delft, a University of Oxford scientist and one of the Moonshot group's leaders. More early discovery work on a range of potential inhibitors for other viruses is also still going on and being funded by a US government grant. "It's a bit like a proof of concept," von Delft says, for bringing a patent-free experimental drug into the clinic, a model that could be repurposed as a tool to fight neglected tropical diseases or antimicrobial resistance, or prepare for future pandemics. "Can we come up with a strategic model that can help those kinds of compounds with less of a business case along?" Of course, there was definitely a business case for a Covid antiviral, and some of the biggest drugmakers rushed to develop them. In 2022, Pfizer Inc.'s Paxlovid was one of the world's best-selling medicines with $18.9 billion in revenue. Demand has since cratered for the pill, which needs to be given shortly after infection and can't be taken alongside a number of other commonly prescribed medicines. Analysts expect the Paxlovid revenue to plunge just shy of $1 billion this year. However, there is still a need for a better Covid antiviral, particularly in countries where access to the Pfizer pill is limited, according to von Delft. Covid cases have surged again this holiday season, with the rise of a new variant called JN.1 reminding us that the virus is still changing to evade the immunity we've built up so far. Just before Christmas, UK authorities said about one in every 24 people in England and Scotland had the disease. An accessible antiviral could help people return to work more quickly, and it could also be tested as a potential treatment for long Covid. "We know from experience in viral disease that there will be resistance variants evolving over time," von Delft said. "We'll need more than one."

Read more of this story at Slashdot.